Literature DB >> 15810650

Is there a relation between irritable Bowel syndrome and urinary stone disease?

Erim Erdem1, Erdem Akbay, Orhan Sezgin, Erdal Doruk, Bülent Canpolat, Selahattin Cayan.   

Abstract

Our aim was to investigate the role of renal colic, a clinical condition characterized by excruciating pain, in the etiopathogenesis of irritable bowel syndrome (IBS). Two groups of patients were enrolled in the study. Group I consisted of 59 patients (33 male and 26 female) with a median age of 41.9 (18 to 58) years. The patients in group I were admitted to our clinic with urinary stone disease and with a medical history of acute renal colic. Group II consisted of 55 patients (25 male and 30 female) with a median age of 40.1 (18 to 56) years, complaining of urologic abnormalities other than stone disease. IBS was diagnosed using Rome criteria. Metabolic analysis for stone disease was performed on patients in group I. The incidence of five metabolic abnormalities--low urine volume, hypercalciuria, hyperoxaluria, hyperuricosuria and hypocitraturia--in patients with and without irritable bowel disease was investigated. IBS was found in 16 of the 59 patients (27.1%) in group I and in 6 of the 55 patients (10.9%) in group II. The difference was statistically significant (P < 0.05). Relative risk of developing IBS was 2.48 times higher in patients with urinary stone disease than in those without stone disease. There was no statistically significant difference in the metabolic analysis of patients with and without IBS in group I. IBS causes great suffering. Urinary stone disease should be considered as an etiological factor during management of IBS patients. In the presence of gastrointestinal symptoms, a patient with a medical history of acute renal colic might be referred to a gastroenterologist.

Entities:  

Mesh:

Year:  2005        PMID: 15810650     DOI: 10.1007/s10620-005-2482-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  7 in total

1.  Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities.

Authors:  G R Locke; A R Zinsmeister; N J Talley; S L Fett; L J Melton
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  Urine stone risk factors in nephrolithiasis patients with and without bowel disease.

Authors:  Joan H Parks; Elaine M Worcester; R Corey O'Connor; Fredric L Coe
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  High prevalence of irritable bowel syndrome in patients attending urological outpatient departments.

Authors:  C Y Francis; J N Duffy; P J Whorwell; J Morris
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

4.  Chronic functional gastrointestinal symptoms in Holocaust survivors.

Authors:  E Stermer; H Bar; N Levy
Journal:  Am J Gastroenterol       Date:  1991-04       Impact factor: 10.864

5.  Comparison of metabolic risk factors in patients with recurrent urolithiasis stratified according to age and gender.

Authors:  T Yagisawa; T Hayashi; A Yoshida; C Kobayashi; H Okuda; N Ishikawa; H Toma
Journal:  Eur Urol       Date:  2000-09       Impact factor: 20.096

6.  Is there an irritable bladder in the irritable bowel syndrome?

Authors:  A K Monga; J M Marrero; S L Stanton; M C Lemieux; J D Maxwell
Journal:  Br J Obstet Gynaecol       Date:  1997-12

7.  Aspects on estimation of the risk of calcium oxalate crystallization in urine.

Authors:  H G Tiselius
Journal:  Urol Int       Date:  1991       Impact factor: 2.089

  7 in total
  2 in total

1.  Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis.

Authors:  Mehmet Rami Helvaci; Mustafa Cem Algin; Hasan Kaya
Journal:  Eurasian J Med       Date:  2009-12

2.  An Initial Attack of Urinary Stone Disease Is Associated with an Increased Risk of Developing New-Onset Irritable Bowel Syndrome: Nationwide Population-Based Study.

Authors:  Wei-Yuan Lei; Chih-Yu Chang; Jr-Hau Wu; Fei-Hung Lin; Cheng Hsu Chen; Chin-Fu Chang; Yan-Ren Lin; Han-Ping Wu
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.